©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Treatment of central sleep apnea in patients with heart failure: Now and future
Azusa Murata, Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Takatoshi Kasai, Department of Cardiovascular Medicine, Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Author contributions: Murata A and Kasai T drafted the manuscript; both authors approved the final version of this article.
Conflict-of-interest statement: Dr. Murata reports to have no conflicts of interest to declare related to this work. Dr. Kasai is affiliated with a department endowed by Philips Respironics, ResMed, and Fukuda Denshi, and is also a member of the Steering Committee of the ADVENT-HF.
Corresponding author: Takatoshi Kasai, MD, PhD, Associate Professor, Department of Cardiovascular Medicine, Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan. kasai-t@mx6.nisiq.net
Telephone: +81-3-38133111
Received: August 30, 2018
Peer-review started: August 30, 2018
First decision: Octorber 26, 2018
Revised: December 13, 2018
Accepted: January 5, 2019
Article in press: January 5, 2019
Published online: January 17, 2019
Processing time: 140 Days and 17.5 Hours
Peer-review started: August 30, 2018
First decision: Octorber 26, 2018
Revised: December 13, 2018
Accepted: January 5, 2019
Article in press: January 5, 2019
Published online: January 17, 2019
Processing time: 140 Days and 17.5 Hours
Core Tip
Core tip: Central sleep apnea (CSA) is commonly comorbid with heart failure (HF). In fact, sleep apnea is associated with a worsening of the cardiac prognosis and an increasing mortality. However, treatment for CSA remains to be elucidated due to the numerous conflicting results of clinical trials. This review attempts to both clarify the current evidence from randomized control trials investigating CSA in patients with HF and highlight the effect of specific CSA treatments on cardiovascular endpoints.